Stoke Therapeutics Stock Forecast, Price & News

+0.23 (+0.80 %)
(As of 08/2/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume116,831 shs
Average Volume168,926 shs
Market Capitalization$1.06 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive STOK News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Stoke Therapeutics logo

About Stoke Therapeutics

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.16 out of 5 stars

Medical Sector

376th out of 2,226 stocks

Pharmaceutical Preparations Industry

186th out of 870 stocks

Analyst Opinion: 3.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Stoke Therapeutics (NASDAQ:STOK) Frequently Asked Questions

Is Stoke Therapeutics a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Stoke Therapeutics stock.
View analyst ratings for Stoke Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Stoke Therapeutics?

Wall Street analysts have given Stoke Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Stoke Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Stoke Therapeutics' next earnings date?

Stoke Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Stoke Therapeutics

How were Stoke Therapeutics' earnings last quarter?

Stoke Therapeutics, Inc. (NASDAQ:STOK) issued its earnings results on Monday, May, 10th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by $0.02.
View Stoke Therapeutics' earnings history

How has Stoke Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Stoke Therapeutics' stock was trading at $19.73 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, STOK shares have increased by 46.3% and is now trading at $28.86.
View which stocks have been most impacted by COVID-19

What price target have analysts set for STOK?

9 Wall Street analysts have issued 12-month price objectives for Stoke Therapeutics' shares. Their forecasts range from $35.00 to $76.00. On average, they expect Stoke Therapeutics' share price to reach $60.14 in the next twelve months. This suggests a possible upside of 108.4% from the stock's current price.
View analysts' price targets for Stoke Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Stoke Therapeutics' key executives?

Stoke Therapeutics' management team includes the following people:
  • Dr. Edward M. Kaye, CEO & Director (Age 72, Pay $958.05k)
  • Dr. Adrian R. Krainer Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board (Age 62, Pay $39k)
  • Mr. Stephen J. Tulipano CPA, CPA, MBA, Chief Financial Officer (Age 62, Pay $611.45k)
  • Dr. Barry S. Ticho FACC, M.D., Ph.D., Chief Medical Officer (Age 61, Pay $662.5k)
  • Ms. Isabel Aznarez Ph.D., Co-Founder & Group VP of Discovery Research (Age 48)
  • Dr. Huw M. Nash Ph.D., COO & Chief Bus. Officer (Age 54)
  • Dr. Gene Liau, Chief Scientific Officer (Age 66)
  • Mr. Jonathan Allan J.D., Deputy Gen. Counsel
  • Ms. Dawn Kalmar, Chief Communications Officer (Age 43)
  • Ms. Joan Wood, Chief HR Officer

Who are some of Stoke Therapeutics' key competitors?

What other stocks do shareholders of Stoke Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA).

When did Stoke Therapeutics IPO?

(STOK) raised $100 million in an IPO on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Stoke Therapeutics' stock symbol?

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Who are Stoke Therapeutics' major shareholders?

Stoke Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Alliancebernstein L.P. (0.05%) and New York State Common Retirement Fund (0.04%). Company insiders that own Stoke Therapeutics stock include Apple Tree Partners Iv, LP, Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Gene Liau, Huw M Nash, Robin A Walker, Rtw Investments, Lp and Stephen J Tulipano.
View institutional ownership trends for Stoke Therapeutics

Which institutional investors are buying Stoke Therapeutics stock?

STOK stock was purchased by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, and Alliancebernstein L.P.. Company insiders that have bought Stoke Therapeutics stock in the last two years include Apple Tree Partners Iv, LP, and Rtw Investments, Lp.
View insider buying and selling activity for Stoke Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Stoke Therapeutics?

Shares of STOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Stoke Therapeutics' stock price today?

One share of STOK stock can currently be purchased for approximately $28.86.

How much money does Stoke Therapeutics make?

Stoke Therapeutics has a market capitalization of $1.06 billion. The company earns $-52,240,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.

How many employees does Stoke Therapeutics have?

Stoke Therapeutics employs 79 workers across the globe.

What is Stoke Therapeutics' official website?

The official website for Stoke Therapeutics is

Where are Stoke Therapeutics' headquarters?

Stoke Therapeutics is headquartered at 45 WIGGINS AVENUE, BEDFORD MA, 01730.

How can I contact Stoke Therapeutics?

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company can be reached via phone at 781-430-8200 or via email at [email protected]

This page was last updated on 8/2/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.